SCHEMBL4665730

SCHEMBL4665730

CCN(CC)C(C)Cn1ccc2cc(-c3cc(Nc4ccc(N(OC=O)S(=O)(=O)c5ccc(OC)c(F)c5)cc4)ncn3)ccc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.34
EGFR P00533 2/20 0.34
ABL1 P00519 6/20 0.33
BCR P11274 6/20 0.33
USP2 O75604 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2D6 P10635 2/20 0.33
ALOX15 P16050 2/20 0.33
CYP2C19 P33261 2/20 0.33
HSD17B10 Q99714 2/20 0.33
CLK4 Q9HAZ1 2/20 0.33
MEN1 O00255 1/20 0.33
TP53 P04637 1/20 0.33
GLA P06280 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
MAPK1 P28482 1/20 0.33
KMT2A Q03164 1/20 0.33
CDK9 P50750 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4663854 0.94 USP2 (0.35) BACE1EGFRABL1BCRUSP2
SCHEMBL4667420 0.89 EGFR (0.39) BACE1EGFRABL1BCRUSP2
SCHEMBL4666172 0.87 BPTF (0.42) EGFRUSP2ALDH1A1CYP1A2CYP2D6
SCHEMBL4663867 0.87 EGFR (0.35) BACE1EGFRABL1BCRUSP2
SCHEMBL4664394 0.87 MEN1 (0.34) BACE1ABL1BCRUSP2ALDH1A1
Formic Acid SCHEMBL4665725 0.87 KIT (0.41) BACE1EGFRABL1BCRTP53
SCHEMBL4667453 0.84 ABL1 (0.34) BACE1EGFRABL1BCRUSP2
Formic Acid SCHEMBL4663852 0.80 KIT (0.42) BACE1ABL1BCRTP53CDK9
SCHEMBL4663849 0.80 MEN1 (0.36) BACE1EGFRABL1BCRUSP2
SCHEMBL4665828 0.79 EGFR (0.46) EGFRABL1BCRUSP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 BACE1 4299/4885EGFR 279/4885ABL1 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.